Biocardia Inc (BCDA)

May 02, 2025

First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo

May 02, 2025

May 02, 2025

Form 8-KCurrent report - ADVFN

May 02, 2025

May 01, 2025

BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq

May 01, 2025

May 01, 2025

BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus

May 01, 2025

May 01, 2025

BioCardia Enrolls First Patient in Phase III Trial - TipRanks

May 01, 2025

May 01, 2025

BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan

May 01, 2025

May 01, 2025

BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus

May 01, 2025

Apr 25, 2025

Biocardia CFO David McClung buys $24,999 in company stock - Investing.com Australia

Apr 25, 2025

Apr 25, 2025

Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com UK

Apr 25, 2025

Apr 25, 2025

BioCardia Executives Increase Their Stakes in the Company - TradingView

Apr 25, 2025

Apr 22, 2025

Biocardia CEO Peter Altman acquires $1,488 in stock - MSN

Apr 22, 2025

Apr 21, 2025

Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com

Apr 21, 2025

Apr 20, 2025

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN

Apr 20, 2025

Apr 18, 2025

Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa

Apr 18, 2025

Apr 17, 2025

Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia

Apr 17, 2025

Apr 16, 2025

DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo

Apr 16, 2025

Apr 15, 2025

BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus

Apr 15, 2025

Apr 15, 2025

Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com

Apr 15, 2025

Apr 15, 2025

BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks

Apr 15, 2025

Apr 15, 2025

BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com

Apr 15, 2025

Apr 15, 2025

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus

Apr 15, 2025

Apr 15, 2025

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times

Apr 15, 2025

Apr 15, 2025

Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan

Apr 15, 2025

Apr 14, 2025

Biocardia CEO Altman purchases shares worth $1,206 - Investing.com Australia

Apr 14, 2025

Apr 14, 2025

Biocardia CEO Altman purchases shares worth $1,206 By Investing.com - Investing.com India

Apr 14, 2025

Apr 14, 2025

Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy - Yahoo Finance

Apr 14, 2025

Apr 12, 2025

BioCardia (BCDA) Advances Phase III CardiAMP HF II Trial with Em - GuruFocus

Apr 12, 2025

Apr 12, 2025

BioCardia Initiates Patient Enrollment at Emory University Schoo - GuruFocus

Apr 12, 2025

Apr 11, 2025

Emory University joins phase III heart failure trial By Investing.com - Investing.com South Africa

Apr 11, 2025

Apr 11, 2025

BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial - marketscreener.com

Apr 11, 2025

Apr 11, 2025

Emory University joins phase III heart failure trial - Investing.com Australia

Apr 11, 2025

Apr 11, 2025

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - The Manila Times

Apr 11, 2025

Apr 11, 2025

Biocardia Initiates Patient Enrollment At Emory University School Of Medicine - MarketScreener

Apr 11, 2025

Apr 08, 2025

BioCardia CEO Peter Altman purchases $980 in company stock By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

BioCardia CEO Peter Altman purchases $980 in company stock - Investing.com

Apr 08, 2025

Apr 08, 2025

BioCardia completes enrollment for heart therapy trial - MSN

Apr 08, 2025

Apr 07, 2025

Biocardia CEO Peter Altman acquires $1,632 in company shares By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

Biocardia CEO Peter Altman acquires $1,632 in company shares - Investing.com Australia

Apr 07, 2025

Apr 05, 2025

Biocardia CEO Peter Altman buys $2,435 in company stock By Investing.com - Investing.com South Africa

Apr 05, 2025

Apr 04, 2025

Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com Australia

Apr 04, 2025

Apr 04, 2025

Biocardia CEO Peter Altman buys $2,435 in company stock - Investing.com Australia

Apr 04, 2025